Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Study of F-627 Prophylaxis in Breast Cancer
NCT02522234Phase 2Completed
- Sponsor
- Evive Biotech
- Start
- Feb 2014
- Primary completion
- Aug 2015
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of efbemalenograstim alfa in neutropenia, sponsored by Evive Biotech. Started Feb 2014; status: completed.
02
Drugs
efbemalenograstim alfa
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT02522234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02522234.